bioAffinity Reports Record Monthly Testing Volume in October
The company performed 235 CyPath Lung tests in October 2026, a 29% increase from October 2025 and approximately 45% of the total quarterly volume. This growth signals continued expansion in commercial reach and physician adoption of the noninvasive lung cancer diagnostic tool.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed